Our EQA study shows that a cartridge-based mRNA assay might offer a reproducible, standardized and time- and tissue-sparing alternative for the evaluation of ESR1 (ER), PGR (PgR), ERBB2 (HER2), and MKI67 (Ki-67) in IBC. Here, MKI67 is linked to inflammatory breast carcinoma.